Precision Medicine Randomized Clinical Trial Comparing Molecular Tumor Board Assisted Care to Usual Care
概览
- 阶段
- 不适用
- 干预措施
- Molecular tumor board assisted care
- 疾病 / 适应症
- Non-Small Cell Lung Cancer
- 发起方
- Timothy Mullett
- 入组人数
- 659
- 试验地点
- 1
- 主要终点
- Overall survival
- 状态
- 进行中（未招募）
- 最后更新
- 上个月
概览
简要总结
This trial will compare Molecular Tumor Board (MTB) assisted care to usual care for patients who have newly diagnosed histologically or cytologically confirmed stage IIb-IV Non-Small Cell Lung Cancer (NSCLC) and are planning to undergo treatment for their cancer.
研究者
Timothy Mullett
Professor
University of Kentucky
入排标准
入选标准
- •Clinically suspected or histologically confirmed stage IIb-IV NSCLC who are planning to undergo treatment
- •No prior systemic therapies for NSCLC, with the exception of adjuvant therapy for early stage NSCLC. Prior surgery and/or radiation is allowed.
- •Ability to understand and the willingness to sign a written informed consent document.
排除标准
- •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with targeted therapy, in the opinion of the treating physician.
- •Pregnancy
研究组 & 干预措施
Molecular tumor board intervention
干预措施: Molecular tumor board assisted care
Usual care recipients
结局指标
主要结局
Overall survival
时间窗: 1 year
Overall survival 1 year survival between individuals with stage IIb-IV NSCLC who receive MTB assisted care to those who receive usual care.
Change in quality of life (QOL)
时间窗: At enrollment, 8 weeks, and 12 weeks.
Quality of life will be assessed via the FACT-L (The Functional Assessment of Cancer Therapy - Lung). FACT-L has 5 areas of measurement: physical wellbeing, social/family wellbeing, emotional wellbeing, functional wellbeing, and an additional concerns list of problems specific to lung cancer. Areas are measured on a 5-point Likert-type scale of 0-4. The FACT-L subscales can be scored to yield a total score, subscale scores, as well as the Trial Outcome Index (TOI), which reflects the physical wellbeing, functional wellbeing, and lung cancer symptom subscales. TOI scores range from 0-84, with a higher score reflecting better QOL. Total FACT-G scores (physical, social, emotional, and functional wellbeing subscales) range from 0-108, with higher scores reflecting better QOL. The lung cancer subscale (i.e., additional concerns subscale) can range from 0-28 (only 7 items are scored), with higher scores reflecting better QOL.
次要结局
- Change in guideline concordant care(8 weeks, 12 weeks, and 1 year)
- Overall survival(1 year)
- Change in satisfaction with treatment(At enrollment, 8 weeks, and 12 weeks.)